Policy Landscape | 2021 | National MCO Analyzer

The Biden Administration will introduce at least six notable changes impacting pharma in 2021. Among his top priorities, Biden will move toward negotiating Medicare drug prices using an international index as a price ceiling, and impose launch and biosimilar price limits. HeÕs supporting drug import initiatives at the state level; intends to eliminate the existing tax deduction for drug advertising costs; and supports proposals to crack down on delay tactics used to block development of generics and biosimilars.